MRS2690

MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA) -, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease[1][2][3][4].

Product Specifications

CAS Number

[7077-89-6]

UNSPSC

12352005

Target

Calcium Channel; P2Y Receptor; p38 MAPK

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

OC[C@H]1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)O)OP(O)(OP(O)(OC[C@@H]2[C@@H](O)[C@@H](O)[C@H](N3C(NC(C=C3)=O)=S)O2)=O)=O

Molecular Formula

C15H24N2O16P2S

Molecular Weight

582.37

References & Citations

[1]Abbas ZSB, et al. UDP-sugars activate P2Y14 receptors to mediate vasoconstriction of the porcine coronary artery. Vascul Pharmacol. 2018 Apr;103-105:36-46.|[2]Gao ZG, et al. UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. Biochem Pharmacol. 2010 Mar 15;79 (6) :873-9. |[3]Gao ZG, et al. The role of P2Y (14) and other P2Y receptors in degranulation of human LAD2 mast cells. Purinergic Signal. 2013 Mar;9 (1) :31-40. |[4]Amison RT, et al. Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y1 and P2Y14 receptors in mice. Pulm Pharmacol Ther. 2017 Aug;45:62-68.